Opinion|Videos|December 10, 2024
First Line Care in CRC
Author(s)Vivek Kaul, MD
Key Takeaways
- Effective communication involves clear, empathetic discussions emphasizing early detection and personalized risk assessment for colorectal cancer screening.
- Providers should consider individual risk factors, preferences, and barriers to adherence when guiding patients in selecting screening options.
Vivek Kaul, MD, discusses how primary care providers can effectively communicate the importance of colorectal cancer screening and guide patients in selecting the most suitable option, and the significant role of patient preferences and adherence in this decision-making process, while also addressing future innovations in screening methods.
Advertisement
- How can primary care providers effectively communicate the importance of colorectal cancer screening and guide patients in selecting the most appropriate option?
- What role do patient preferences and adherence play in choosing a colorectal cancer screening method?
- What are future innovations in the colorectal cancer space?
Advertisement
Related to this article
Sarina Berger Elmariah, MD, PhD, MPH, discusses 3-year nemolizumab data in early responders and what IL-31 blockade means for itch and atopic dermatitis.
Participants described how comorbidities, payer formularies, and patient preference shape biologic choice in asthma and COPD.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, recap the first-ever Breakthrough T1D Clinical and Research Congress.
Alpha-gal syndrome is reaching new regions, but delayed reactions and GI-only symptoms can leave patients undiagnosed for months or years.
Repeated oral steroid bursts are the main trigger for starting a biologic, while therapy for non-type 2 inflammation COPD remains an unmet need.
At Fall Clinical 2026, Aaron S. Farberg, MD, shares how gene expression testing guides melanoma and atopic dermatitis care and what Ameluz PDT adds.
A roundup of updates spanning PsO, atopic dermatitis, alopecia areata, vitiligo, palmoplantar pustulosis, cutaneous sarcoidosis, and discoid lupus.
Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.
Advertisement
Advertisement
Trending on HCPLive
1
Tezepelumab Meets Co-Primary End Points in Phase 3 CROSSING Trial in EoE
2
52-Week Litifilimab Data in Cutaneous Lupus Erythematosus
3
Mirikizumab Shows Early Efficacy in Pediatric UC in SHINE-2 Trial
4
Tenapanor Linked to Lower IBS-C Care Use, With Kyle Staller, MD, MPH
5